A new study further validates the use of humanized BLT mice in the fight to block HIV transmission. Humanized BLT mice have a fully functioning human immune system and can be infected with HIV in the same manner as humans.
Researchers have used cells found naturally in the body, to re-educate the immune system to prevent rejection of an organ transplant while remaining capable of fighting infections and cancer.
An NIH-funded study has found that despite their beneficial effects in treating heart disease, neither aspirin nor simvastatin appear to offer benefit to patients suffering from pulmonary artery hypertension.
Research physicians believe that a new treatment regimen for patients with metastatic colon cancer appears to offer clinical benefit even when used after multiple other treatments have failed.
Quay Pharmaceuticals has invested in a variety of new equipment as part of its move to its purpose-designed facility in Deeside, U.K., which was officially opened last year.
Pharmatek Laboratories, Inc. has added spray drying to its drug formulation and manufacturing capabilities, purchasing a Buchi B-290 Mini Spray Dryer for formulation feasibility studies and small-scale clinical manufacture.
ERT has signed three contracts with pharmaceutical companies for its electronic patient reported outcomes (ePRO) business , totaling over $10 million.
DaVita Clinical Research has completed a Phase I-IIa cleanroom to comply with USP 797 high risk regulations demonstrating the cleanroom meets the requirements to handle compounds in a safe and efficient manner.
PPD, Inc. announced it has established four practice areas through PPD Consulting-biosimilars, adaptive trial design, China regulatory strategy, and cardiovascular outcomes studies.
Harman Dubé has joined Ockham as vice-president of pre-clinical and regulatory affairs within the OckhamCRO division.
ERT, appointed Jeffrey S. Litwin, MD as its new president and chief executive officer and as a member of the board.
Kole has joined Almac’s Clinical Technologies business unit as vice president of Clinical Project Services (CPS) and a member of the executive leadership team.
Genentech reported that data showing new personalized approaches for skin and lung cancer patients, plus new data with Avastin (bevacizumab) in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7.
Allon Therapeutics Inc. has updated the progress of a Phase 2/3 clinical trial that is evaluating the company's lead neuroprotective drug candidate, davunetide as a potential treatment for progressive supranuclear palsy (PSP), a rapidly-progressing and fatal degenerative brain disease.
Takeda Pharmaceutical Co. said it will buy Switzerland's Nycomed for $13.6 billion, in an all-cash deal that is the largest ever overseas takeover by a Japanese pharmaceutical company.